Last update: July 2, 2015
Minimal risk for breastfeeding and infant.
Centrally acting Myorelaxant.
Indicated for spastic disorders associated with degenerative illnesses and cerebral palsy.
Excreted into breast milk in non-significant clinical amount with no harm effects reported among breastfed infants from treated mothers.
When administered in pregnancy, symptoms of Abstinence Syndrome may appear,
Intrathecal administration shows small serum levels by which it is assumed that the amount present in breast milk must be even lower.
Oral administration has been authorized since neonatal age in the UK and one year of life in Spain.
Follow-up of milk production is recommended since a theoretically based inhibition of Prolactin may occur.
American Academy of Pediatrics: medication usually compatible with breastfeeding.
We do not have alternatives for Baclofen since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM